Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
J Biol Chem. 2011 May 27;286(21):18573-82. doi: 10.1074/jbc.M110.200717. Epub 2011 Apr 6.
Mammary cancer stem cells (MaCSCs) have been identified as a rare population of cells capable of self-renewal to drive mammary tumorigenesis and metastasis. Nevertheless, relatively little is known about the intracellular signaling pathways regulating self-renewal and metastatic activities of MaCSCs in vivo. Using a recently developed breast cancer mouse model with focal adhesion kinase (FAK) deletion in mammary tumor cells (MFCKO-MT mice), here we present evidence suggesting a compensatory function of Pyk2, a FAK-related kinase, in the regulation of MaCSCs and metastasis in these mice. Increased expression of Pyk2 was found selectively in pulmonary metastatic nodules of MFCKO-MT mice, and its inhibition significantly reduced mammary tumor development and metastasis in these mice. Consistent with the idea of metastasis driven by MaCSCs, we detected selective up-regulation of Pyk2 in MaCSCs, but not bulk mammary tumor cells, of primary tumors developed in MFCKO-MT mice. We further showed that inhibition of Pyk2 in FAK-null MaCSCs significantly decreased their tumorsphere formation and migration in vitro as well as self-renewal, tumorigenicity, and metastatic activity in vivo. Last, we identified PI3K/Akt signaling as a major mediator of FAK regulation of MaCSCs as well as a target for the compensatory function of Pyk2 in FAK-null MaCSCs. Together, these results further advance our understanding of FAK and its related tyrosine kinase Pyk2 in regulation of MaCSCs in breast cancer and suggest that pharmaceutically targeting these kinases may hold promise as a novel treatment for the disease by targeting and eradicating MaCSCs.
乳腺癌干细胞(MaCSCs)已被鉴定为一种能够自我更新以驱动乳腺癌发生和转移的罕见细胞群体。然而,关于调节 MaCSCs 体内自我更新和转移活性的细胞内信号通路,人们知之甚少。本研究利用最近开发的乳腺癌小鼠模型,该模型中乳腺肿瘤细胞中 focal adhesion kinase(FAK)缺失(MFCKO-MT 小鼠),研究结果表明 FAK 相关激酶 Pyk2 在调节 MaCSCs 和这些小鼠转移中具有代偿功能。研究发现,MFCKO-MT 小鼠肺转移结节中 Pyk2 的表达选择性增加,其抑制显著降低了这些小鼠的乳腺肿瘤发生和转移。与 MaCSCs 驱动转移的观点一致,研究人员在 MFCKO-MT 小鼠原发肿瘤的 MaCSCs 中检测到 Pyk2 的选择性上调,而在大块乳腺肿瘤细胞中则没有。研究人员进一步表明,在 FAK 缺失的 MaCSCs 中抑制 Pyk2 显著降低了它们在体外的肿瘤球形成和迁移以及体内的自我更新、致瘤性和转移活性。最后,研究人员确定 PI3K/Akt 信号通路是 FAK 调节 MaCSCs 的主要介质,也是 Pyk2 在 FAK 缺失的 MaCSCs 中发挥代偿功能的靶点。综上所述,这些结果进一步加深了对 FAK 及其相关酪氨酸激酶 Pyk2 在乳腺癌中调节 MaCSCs 的理解,并表明通过靶向和根除 MaCSCs,靶向这些激酶可能为该疾病的治疗提供新的希望。